Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, with the proviso that a carbon atom on the ring is attached to the carbonyl carbon;

R^1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^2 is a substituent attached to Ring B and is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each n is an integer of 1 to 10; and

each m is an integer of 1 to 5.

[0023a] In a first aspect, there is provided a compound of Formula **Ia**:



Ia

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is  ;

Ring B is selected from the group consisting of  , and ;

each R^1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2a} is selected from the group consisting of unsubstituted –C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, Cl, Br, I, -OR^{3a}, CF_3, and CN;

R^{2b} is selected from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^{3a}, CF_3, and CN;

R^{2c} is 2-5 substituents, each independently selected at each occurrence from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2d} is 1-4 substituents, each independently selected at each occurrence from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2e} is 1-4 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2f} is 1-3 substituents, each independently selected at each occurrence from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2g} is 1-3 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3a} is independently selected from the group consisting of unsubstituted –C_{2-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each W is N or C, wherein at least two W are N;

each U is N or C, wherein at least one U is N and at least one U is C;

G is NH or O;

each J is N or C, wherein at least one J is C; and

n is an integer of 1 to 7.

[0023b] In a second aspect, there is provided a compound of Formula **Ib**:



Ib

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is 

;

Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^2 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each M is independently selected from the group consisting of N, C, S and O, wherein both M are not O and both M are not C;

m is an integer of 1 to 5; and

n is an integer of 1 to 10.

[0023c] In a third aspect, there is provided a compound of Formula **Ic**:



Ic

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is 

;

Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^2 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each M is independently selected from the group consisting of N, C, S and O, wherein if one M is C, the other M is selected from the group consisting of N, S, and O;

m is an integer of 1 to 5; and

n is an integer of 1 to 10.

[0023d] In a fourth aspect, there is provided a compound of Formula **Id**:



Id

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is 

;

Ring B is selected from the group consisting of 

, 

, 

, 

, and a 5-6 membered heteroarylR^{2e}, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2a} is selected from the group consisting of H, unsubstituted –C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, Cl, Br, I, -OR^{3a}, CF_3, and CN;

R^{2b} is selected from the group consisting of H, unsubstituted –C_{2-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, F, I, -OR^3, CF_3, and CN;

R^{2c} is selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, F, Br, I, -OR^3, CF_3, and CN;

R^{2d} is 2-5 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2e} is 1-3 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3a} is independently selected from the group consisting of H, unsubstituted –C_{2-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

Q is S or NH; and

n is an integer of 1 to 5.

[0023e] In a fifth aspect, there is provided a compound of Formula **Ie**:



Ie

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is  ;

Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^2 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each W is N or C, wherein at least one W is N;

Q is S or NH;

m is an integer of 1 to 5; and

n is an integer of 1 to 4.

[0023f] In a sixth aspect, there is provided a compound of Formula **If**:



If

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is  ;

Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^2 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each W is N or C;

m is an integer of 1 to 5; and

n is an integer of 1 to 5.

[0023g] In a seventh aspect, there is provided a compound of Formula **Ig**:



Ig

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is 

;

Ring B is selected from the group consisting of 

, 

, and a 5-6 membered heteroarylR^{2d}, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2a} is selected from the group consisting of unsubstituted –C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, F, I, -OR^3, CF_3, and CN;

R^{2b} is selected from the group consisting of unsubstituted –C_{2-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2c} is 2-5 substituents, each independently selected at each occurrence from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2d} is 1-3 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted $-C_{1-3}$ alkyl;

Q is selected from the group consisting of O, S, and NH; and

n is an integer of 1 to 5.

[0023h] In an eighth aspect, there is provided a compound of Formula **Ih**:



Ih

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is 

;

Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein at a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted $-C_{1-6}$ alkyl, $-C_{1-3}$ haloalkyl, halide, $-OR^3$, CF_3, and CN;

each R^2 is independently selected at each occurrence from the group consisting of H, unsubstituted $-C_{1-6}$ alkyl, $-CH_2OH$, $-CH_2N(R^{3b})_2$, $-C_{1-3}$ haloalkyl, halide, $-OR^3$, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted $-C_{1-6}$ alkyl, $-C_{1-3}$ haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted $-C_{1-3}$ alkyl;

each W is N or C, wherein at least one W is N;

Q is selected from the group consisting of O, S, and NH;

m is an integer of 1 to 5; and

n is an integer of 1 to 4.

[0023i] In a ninth aspect, there is provided a compound of Formula **Ii**:



Ii

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is  , wherein a carbon atom on the ring is attached to the carbonyl carbon;

Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^2 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each W is N or C, wherein at least one W is C;

Q is selected from the group consisting of O, S, and N;

m is an integer of 1 to 5; and

n is an integer of 1 to 7.

[0023j] In a tenth aspect, there is provided a pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of the first to ninth aspects, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0023k] In an eleventh aspect, there is provided use of a therapeutically effective amount of a compound according to any of the first to ninth aspects, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disorder or disease in a patient, wherein the disorder or disease is selected from the group consisting of a neurodegenerative disease, eye disease, osteoporosis, osteoarthropathy, osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, oral mucositis, gastrointestinal mucositis, craniofacial defects, and oncolytic bone disease.

[0023l] In a twelfth aspect, there is provided use of a therapeutically effective amount of a compound according to any of the first to ninth aspects, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disorder or disease in a patient, wherein the disorder or disease is related to differentiation and growth of stem cells such as alopecia, hair loss, hematopoiesis related diseases, tissue regeneration related diseases and other diseases associated with abnormalities in development, stem cell differentiation and cell proliferation.

[0023m] In a thirteenth aspect, there is provided a compound-eluting coating or a controlled release system comprising a compound according to any one of the first to ninth aspects, or a pharmaceutically acceptable salt thereof.

[0023n] In a fourteenth aspect, there is provided a medical device comprising a compound according to any one of the first to ninth aspects, or a pharmaceutically acceptable salt thereof.

[0023o] In a fifteenth aspect, there is provided an implant, sponge, polymer, ointment, cream or gel composition suitable for *in vivo* use comprising a compound according to any one of the first to ninth aspects, or a pharmaceutically acceptable salt thereof.

[0024] Another embodiment of a *Wnt*/β-catenin signaling pathway activator disclosed herein includes compounds of Formula **II**:



II

or a pharmaceutically acceptable salt thereof.

[0025] In some embodiments of Formula **II**:

Ring C is a 5-6 membered heteroaryl, with the proviso that a carbon atom on the ring is attached to the carbonyl carbon;

Ring D is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, with the proviso that a carbon atom on the ring is attached to the carbonyl carbon;

R^4 is a substituent attached to Ring C and is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^6, CF_3, and CN;

WHAT IS CLAIMED IS:

1. A compound of Formula **I**:



I

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is a 7-12 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon;

Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon;

R^1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^2 is a substituent attached to Ring B and is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each n is an integer of 1 to 10; and

each m is an integer of 1 to 5;

with the proviso that the compound of Formula **I** is not a compound selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

, and

.

2. The compound of claim 1, wherein Ring A is a 9-membered bicyclic heteroaryl ring containing 1-3 heteroatoms selected from the group consisting of N, O, and S.

3. The compound of any one of claims 1-2, wherein Ring A is selected from the group consisting of

,

,

,

,

,

,

,

,

,

, and

.

4. The compound of any one of claims 1-3, wherein Ring A is selected from the group consisting of

,

,

,

,

,

,
and

.

5. The compound of any one of claims 1-4, wherein Ring A is selected from the group consisting of  ,  , and  .

6. The compound of any one of claims 1-5, wherein Ring A is a 10-membered bicyclic heteroaryl ring containing 1-3 heteroatoms selected from the group consisting of N, O, and S.

7. The compound of any one of claims 1-6, wherein Ring A is selected from the group consisting of  ,  ,  ,  , and  .

8. The compound of any one of claims 1-7, wherein Ring A is selected from the group consisting of  and  .

9. The compound of any one of claims 1-8, wherein R^1 is selected from the group consisting of H, F, Cl, Me, OMe, OH, CF_3 and CN; and n is 1 or 2.

10. The compound of any one of claims 1-9, wherein R^1 is H.

11. The compound of any one of claims 1-10, wherein R^1 is F; and n is 1.

12. The compound of any one of claims 1-11, wherein Ring B is phenyl.

13. The compound of any one of claims 1-12, wherein  is selected from the group consisting of  ,  ,  ,  ,  ,  , and  ; and m is 1 or 2.

14. The compound of any one of claims 1-13, wherein  is selected from the group consisting of  ,  , and .

15. The compound of any one of claims 1-14, wherein Ring B is a 5-membered heteroaryl containing 1-3 heteroatoms selected from the group consisting of N, O, and S.

16. The compound of any one of claims 1-15, wherein  is selected from the group consisting of  ,  , and ; and m is 1 or 2.

17. The compound of any one of claims 1-16, wherein R^2 is H.

18. The compound of any one of claims 1-17, wherein R^2 is F; and m is 1.

19. The compound of any one of claims 1-18, wherein  is selected from the group consisting of  and ; and R^2 is H.

20. The compound of any one of claims 1-19, wherein Ring B is a 6-membered heteroaryl containing 1-2 nitrogen atoms.

21. The compound of any one of claims 1-20, wherein  is selected from the group consisting of  ; and m is 1 or 2.

22. The compound of any one of claims 1-21, wherein R^2 is H.

23. The compound of any one of claims 1-22, wherein R^2 is F; and m is 1.

24. The compound of any one of claims 1-23, wherein  is selected from the group consisting of  ,  ,  , and  ; and R^2 is H.

25. The compound of any one of claims 1-24, wherein the compound of Formula **I** is selected from the group consisting of:




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,































































,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,









, and 
,

or a pharmaceutically acceptable salt thereof.

26. A compound of Formula **Ia**:



Ia

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is  ;

Ring B is selected from the group consisting of 










, and 
;

each R^1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2a} is selected from the group consisting of unsubstituted –C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, Cl, Br, I, -OR^{3a}, CF_3, and CN;

R^{2b} is selected from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^{3a}, CF_3, and CN;

R^{2c} is 2-5 substituents, each independently selected at each occurrence from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2d} is 1-4 substituents, each independently selected at each occurrence from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2e} is 1-4 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2f} is 1-3 substituents, each independently selected at each occurrence from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2g} is 1-3 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3a} is independently selected from the group consisting of unsubstituted –C_{2-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each W is N or C, wherein at least two W are N;

each U is N or C, wherein at least one U is N and at least one U is C;

G is NH or O;

each J is N or C, wherein at least one J is C; and

n is an integer of 1 to 7.

27. The compound of claim 26, wherein the compound of Formula **Ia** is selected from the group consisting of:













or a pharmaceutically acceptable salt thereof.

28. A compound of Formula **Ib**:



Ib

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is 

;

Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^2 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each M is independently selected from the group consisting of N, C, S and O, wherein both M are not O and both M are not C;

m is an integer of 1 to 5; and

n is an integer of 1 to 10.

29. The compound of claim 28, wherein the compound of Formula **Ib** is selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,











or a pharmaceutically acceptable salt thereof.

30. A compound of Formula **Ic**:



Ic

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is  ;

Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^2 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each M is independently selected from the group consisting of N, C, S and O, wherein if one M is C, the other M is selected from the group consisting of N, S, and O;

m is an integer of 1 to 5; and

n is an integer of 1 to 10.

31. The compound of claim 30, wherein the compound of Formula **Ic** is selected from the group consisting of:







or a pharmaceutically acceptable salt thereof.

32. A compound of Formula **Id**:



Id

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is  ;

Ring B is selected from the group consisting of  ,  , and a 5-6 membered heteroarylR^{2e}, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2a} is selected from the group consisting of H, unsubstituted –C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, Cl, Br, I, -OR^{3a}, CF_3, and CN;

R^{2b} is selected from the group consisting of H, unsubstituted –C_{2-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, F, I, -OR^3, CF_3, and CN;

R^{2c} is selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, F, Br, I, -OR^3, CF_3, and CN;

R^{2d} is 2-5 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2e} is 1-3 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3a} is independently selected from the group consisting of H, unsubstituted –C_{2-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

Q is S or NH; and

n is an integer of 1 to 5.

33. The compound of claim 32, wherein the compound of Formula **Id** is selected from the group consisting of:



or a pharmaceutically acceptable salt thereof.

34. A compound of Formula **Ie**:



Ie

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is  ;

Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^2 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each W is N or C, wherein at least one W is N;

Q is S or NH;

m is an integer of 1 to 5; and

n is an integer of 1 to 4.

35. The compound of claim 34, wherein the compound of Formula **Ie** is selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

, and

,

or a pharmaceutically acceptable salt thereof.

36. A compound of Formula **If**:



If

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is  ;

Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^2 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each W is N or C;

m is an integer of 1 to 5; and

n is an integer of 1 to 5.

37. A compound of Formula **Ig**:



Ig

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is  ;

Ring B is selected from the group consisting of  ,  ,  ,  , and a 5-6 membered heteroarylR^{2d}, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2a} is selected from the group consisting of unsubstituted –C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, F, I, -OR^3, CF_3, and CN;

R^{2b} is selected from the group consisting of unsubstituted –C_{2-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2c} is 2-5 substituents, each independently selected at each occurrence from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2d} is 1-3 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

Q is selected from the group consisting of O, S, and NH; and

n is an integer of 1 to 5.

38. A compound of Formula **Ih**:



Ih

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is  ;

Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein at a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^2 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each W is N or C, wherein at least one W is N;

Q is selected from the group consisting of O, S, and NH;

m is an integer of 1 to 5; and

n is an integer of 1 to 4.

39. A compound of Formula **Ii**:



Ii

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is  , wherein a carbon atom on the ring is attached to the carbonyl carbon;

Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^2 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each W is N or C, wherein at least one W is C;

Q is selected from the group consisting of O, S, and N;

m is an integer of 1 to 5; and

n is an integer of 1 to 7.

40. The compound of claim 39, wherein the compound of Formula **Ii** is selected from the group consisting of:

 ,  ,  ,

 ,  ,  ,







































and

or a pharmaceutically acceptable salt thereof.

41. A compound of Formula II:



II

or a pharmaceutically acceptable salt thereof,

wherein:

Ring C is a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon;

Ring D is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^4 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^6, CF_3, and CN;

each R^5 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, halide, -OR^6, CF_3, and CN;

each R^6 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{6b} is independently selected from the group consisting of H and unsubstituted -C_{1-3} alkyl;

p is an integer of 1 to 4; and

q is an integer of 1 to 5.

with the proviso that the compound of Formula **II** is not a compound selected from the group consisting of:







, and .

42. The compound of claim 41, wherein Ring C is a 5-membered heteroaryl ring containing 1-3 heteroatoms selected from the group consisting of N, O, and S.

43. The compound of any one of claims 41-42, wherein  is selected from the group consisting of  ,  ,  ,  ; and p is 1 or 2.

44. The compound of any one of claims 41-43, wherein  is .

45. The compound of any one of claims 41-44, wherein Ring C is a 6-membered heteroaryl ring containing 1-2 nitrogens.

46. The compound of any one of claims 41-45, wherein  is selected from the group consisting of  ; and p is 1 or 2.

47. The compound of any one of claims 41-46, wherein  is  .

48. The compound of any one of claims 41-47, wherein R^4 is selected from the group consisting of H, F, Cl, Me, OMe, OH, CF_3, and CN; and p is 1 or 2.

49. The compound of any one of claims 41-48, wherein R^4 is H.

50. The compound of any one of claims 41-49, wherein R^4 is F; and p is 1.

51. The compound of any one of claims 41-50, wherein Ring D is phenyl.

52. The compound of any one of claims 41-51, wherein  is selected from the group consisting of  ,  ,  ,  ,  ,  , and  ; and q is 1 or 2.

53. The compound of any one of claims 41-52, wherein  is selected from the group consisting of  ,  ,  ,  ,  ,  ,  , and  .

54. The compound of any one of claims 41-53, wherein Ring D is a 5-membered heteroaryl containing 1-3 heteroatoms selected from the group consisting of N, O, and S.

55. The compound of any one of claims 41-54, wherein  is selected from the group consisting of  ,  ,  ,  ,  ,  ,  ,  , and  ; and q is 1 or 2.

56. The compound of any one of claims 41-55, wherein R^5 is H.

57. The compound of any one of claims 41-56, wherein R^5 is F; and q is 1.

58. The compound of any one of claims 41-57, wherein  is selected from the group consisting of  and  .

59. The compound of any one of claims 41-58, wherein Ring B is a 6-membered heteroaryl containing 1-2 nitrogen atoms.

60. The compound of any one of claims 41-59, wherein  is selected from the group consisting of  ; and q is 1 or 2.

61. The compound of any one of claims 41-60, wherein R^5 is H.

62. The compound of any one of claims 41-61, wherein R^5 is F; and q is 1.

63. The compound of any one of claims 41-62, wherein  is selected from the group consisting of  ; and R^5 is H.

64. The compound of any one of claims 41-63, wherein the compound of Formula **II** is selected from the group consisting of:




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,





























, and

or a pharmaceutically acceptable salt thereof.

65. A compound of Formula **IIa**:



IIa

or a pharmaceutically acceptable salt thereof,

wherein:

Ring C is  ;

Ring D is selected from the group consisting of  ,  ,  ,  ,  , and  , wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^4 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^6, CF_3, and CN;

R^{5a} is 1-5 substituents, each independently selected at each occurrence from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, halide, -OR^{6a}, CF_3, and CN;

R^{5b} is 1-4 substituents, each independently selected at each occurrence from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, F, I, -OR^{6a}, CF_3, and CN;

R^{5c} is 1-3 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, halide, -OR^6, CF_3, and CN;

R^{5d} is 1-2 substituents, each independently selected at each occurrence from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, halide, -OR^6, CF_3, and CN;

R^{5e} is 1-3 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, halide, -OR^6, CF_3, and CN;

each R^6 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{6a} is independently selected from the group consisting of H, unsubstituted –C_{2-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{6b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each A is N or C, wherein at least two A are N;

each J is N or C, wherein at least one J is N and at least one J is C;

each U is N or C, wherein at least one U is C;

Q is O or N; and

p is an integer of 1 to 4.

66. The compound of claim 65, wherein the compound of Formula **IIa** is selected from the group consisting of:




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,




and


or a pharmaceutically acceptable salt thereof.

67. A compound of Formula **IIb**:



IIb

or a pharmaceutically acceptable salt thereof,

wherein:

Ring C is  ;

Ring D is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^4 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^{6a}, CF_3, and CN;

each R^5 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, halide, -OR^6, CF_3, and CN;

each R^6 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{6a} is independently selected from the group consisting of unsubstituted –C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{6b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each A is N or C, wherein at least two A are N;

p is an integer of 1 to 3; and

q is an integer of 1 to 5.

68. The compound of claim 67, wherein the compound of Formula **IIb** is selected from the group consisting of:









or a pharmaceutically acceptable salt thereof.

69. A compound of Formula **IIc**:



IIc

or a pharmaceutically acceptable salt thereof,

wherein:

Ring C is  ;

Ring D is selected from the group consisting of  ,  ,  ,  ,  , and  , wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^4 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^6, CF_3, and CN;

R^{5a} is selected from the group consisting of unsubstituted –C_{2-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{2-3} haloalkyl, iodide, -OR^{6a}, and CN;

R^{5b} is selected from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{2-3} haloalkyl, halide, -OR^{6a}, and CN;

R^{5c} is selected from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, F, Br, I, -OR^{6a}, CF_3, and CN;

R^{5d} is is 2-5 substituents, each independently selected at each occurrence from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, halide, -OR^{6a}, CF_3, and CN;

R^{5e} is 1 substituent and selected from the group consisting of unsubstituted –C_{2-5} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, F, I, -OR^6, CF_3, and CN;

R^{5f} is 1-2 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, F, Br, I, -OR^6, CF_3, and CN;

R^{5g} is 1-3 substituents, each independently selected at each occurrence from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, halide, -OR^6, CF_3, and CN;

R^{5h} is 1-2 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, halide, -OR^6, CF_3, and CN;

R^{5i} is 1-4 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, halide, -OR^6, CF_3, and CN;

each R^6 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{6a} is independently selected from the group consisting of unsubstituted –C_{2-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{6b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each J is N or C, wherein at least one J is C;

Q is S or O;

each U is N or C, wherein at least one U is N and at least one U is C; and

p is an integer of 1 to 3.

70. The compound of claim 69, wherein the compound of Formula **IIc** is selected from the group consisting of:







and


or a pharmaceutically acceptable salt thereof.

71. A compound of Formula **IId**:



IId

or a pharmaceutically acceptable salt thereof,

wherein:

Ring C is  ;

Ring D is selected from the group consisting of  ,  ,  , and  , wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^4 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^6, CF_3, and CN;

R^{5a} is 1 substituent and selected from the group consisting of unsubstituted –C_{2-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, halide, -OR^{6a}, and CN;

R^{5b} is 1-4 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, halide, -OR^{6a}, CF_3, and CN;

R^{5c} is 1-3 substituents, each independently selected at each occurrence from the group consisting of unsubstituted –C_{2-5} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, halide, -OR^6, CF_3, and CN;

R^{5d} is 1-2 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, halide, -OR^6, CF_3, and CN;

R^{5e} is 1-4 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, halide, -OR^6, CF_3, and CN;

each R^6 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{6a} is independently selected from the group consisting of unsubstituted –C_{2-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{6b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each J is N or C, wherein at least one J is N and at least one J isC;

Q is S or O;

each U is N or C, wherein at least one U is C; and

p is an integer of 1 to 3.

72. The compound of claim 71, wherein the compound of Formula **IId** is selected from the group consisting of:



and


,

or a pharmaceutically acceptable salt thereof.

73. A compound of Formula **IIe**:



IIe

or a pharmaceutically acceptable salt thereof,

wherein:

Ring C is  , wherein a carbon atom on the ring is attached to the carbonyl carbon;

Ring D is selected from the group consisting of  ,  ,  and , wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^4 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^6, CF_3, and CN;

R^{5a} is selected from the group consisting of H, unsubstituted –C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, F, Br, I, -OR^6, CF_3, and CN;

R^{5b} is 1-4 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, halide, -OR^6, CF_3, and CN;

R^{5c} is 1-4 substituents, each independently selected at each occurrence from the group consisting of unsubstituted –C_{2-5} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, halide, -OR^6, CF_3, and CN;

R^{5d} is 1-2 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted –C_{2-6} alkyl, -CH_2OH, -$CH_2N(R^{6b})_2$, -C_{1-3} haloalkyl, halide, -OR^{6a}, CF_3, and CN;

each R^6 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{6a} is independently selected from the group consisting of unsubstituted $-C_{1-6}$ alkyl, $-C_{1-3}$ haloalkyl, and CF_3;

each R^{6b} is independently selected from the group consisting of H and unsubstituted $-C_{1-3}$ alkyl;

each A is N or C, wherein at least one A is C;

each U is N or C, wherein at least one U is N and at least one U is C;

p is an integer of 1 to 4.

74. A compound of Formula **IIf**:



IIf

or a pharmaceutically acceptable salt thereof;

wherein:

Ring C is  , wherein a carbon atom on the ring is attached to the carbonyl carbon;

Ring D is selected from the group consisting of  and a 5-membered heteroarylR^{5b}, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^4 is independently selected at each occurrence from the group consisting of H, unsubstituted $-C_{1-6}$ alkyl, $-C_{1-3}$ haloalkyl, halide, $-OR^6$, CF_3, and CN;

R^{5a} is 1-5 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted $-C_{1-6}$ alkyl, $-CH_2OH$, $-CH_2N(R^{6b})_2$, $-C_{1-3}$ haloalkyl, halide, $-OR^{6a}$, CF_3, and CN;

R^{5b} is 1-4 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted $-C_{1-6}$ alkyl, $-CH_2OH$, $-CH_2N(R^{6b})_2$, $-C_{1-3}$ haloalkyl, halide, $-OR^6$, CF_3, and CN;

each R^6 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{6a} is independently selected from the group consisting of unsubstituted –C_{2-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{6b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each A is N or C, wherein at least one A is N and at least one A is C;

Q is S or O; and

p is an integer of 1 to 4.

75. A compound of Formula **IIIa**:



IIIa

or a pharmaceutically acceptable salt thereof,

wherein:

R^{10} is selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^{13}, CF_3, and CN;

R^{11} is selected from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{13b})_2$, -C_{1-3} haloalkyl, halide, -OR^{13}, CF_3, and CN;

each R^{12} is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{13b})_2$, -C_{1-3} haloalkyl, halide, -OR^{13}, CF_3, and CN;

each R^{13} is independently selected from the group consisting of unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{13b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl; and

q is an integer of 1 to 5;

with the proviso that the compound of Formula **IIIa** is not a compound selected from the group consisting of:



, and .

76. The compound of claim 75, wherein R^{10} is selected from the group consisting of H, F, Cl, Me, OMe, CF_3, and CN.

77. The compound of any one of claims 75-76, wherein R^{11} is selected from the group consisting of H, F, Cl, Me, OMe, CF_3, and CN.

78. The compound of any one of claims 75-77, wherein R^{10} is H; and R^{11} is F.

79. The compound of any one of claims 75-78, wherein R^{10} is H;, and R^{11} is CF_3.

80. The compound of any one of claims 75-79, wherein R^{10} is F; and R^{11} is F.

81. The compound of any one of claims 75-80, wherein R^{10} is F; and R^{11} is CF_3.

82. The compound of any one of claims 75-81, wherein R^{12} is selected from the group consisting of H, F, Cl, Me, OMe, CF_3, and CN.

83. The compound of any one of claims 75-82, wherein R^{12} is H.

84. The compound of any one of claims 75-83, wherein R^{12} is F or Cl; and q is 1.

85. The compound of any one of claims 75-84, wherein R^{12} is CF_3; and q is 1.

86. The compound of any one of claims 75-85, wherein the compound of Formula **IIIa** is selected from the group consisting of:



or a pharmaceutically acceptable salt thereof.

87. A compound , of Formula **IIIb**:



IIIb

or a pharmaceutically acceptable salt thereof,

wherein:

R^{14} is selected from the group consisting of unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

R^{15} is selected from the group consisting of unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{16} is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{17b})_2$, -C_{1-3} haloalkyl, halide, -OR^{17}, CF_3, and CN;

each R^{17} is independently selected from the group consisting of unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{17b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl; and

q is an integer of 1 to 5;

with the proviso that the compound of Formula **IIIb** is not a compound selected from the group consisting of:



, 

, and 

.

88. The compound of claim 87, wherein R^{14} is -C_{1-6} alkyl.

89. The compound of any one of claims 87-88, wherein R^{14} is Me.

90. The compound of any one of claims 87-89, wherein R^{15} is -C_{1-6} alkyl.

91. The compound of any one of claims 87-90, wherein R^{15} is Me.

92. The compound of any one of claims 87-91, wherein R^{16} is selected from the group consisting of H, F, Cl, Me, OMe, CF_3, and CN.

93. The compound of any one of claims 87-92, wherein R^{16} is H.

94. The compound of any one of claims 87-93, wherein R^{16} is F or Cl; and q is 1.

95. The compound of any one of claims 87-94, wherein R^{16} is CF_3; and q is 1.

96. The compound of any one of claims 87-95, wherein the compound of Formula **IIIb** is selected from the group consisting of:



, and

or a pharmaceutically acceptable salt thereof.

97. A compound of Formula **IIIc**:



IIIc

or a pharmaceutically acceptable salt thereof,

wherein:

Ring E is selected from the group consisting of  ,  ,  , and  ;

R^{10} is selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^{13}, CF_3, and CN;

R^{11} is selected from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{13b})_2$, -C_{1-3} haloalkyl, halide, -OR^{13}, CF_3, and CN;

R^{12a} is selected from the group consisting of unsubstituted –C_{2-6} alkyl, -CH_2OH, -$CH_2N(R^{13b})_2$, -C_{2-3} haloalkyl, Cl, I, -OEt, and CN;

R^{12b} is selected from the group consisting of unsubstituted –C_{2-6} alkyl, -CH_2OH, -$CH_2N(R^{13b})_2$, -C_{1-3} haloalkyl, iodide, -OR^{13a}, and CF_3;

R^{12c} is selected from the group consisting of unsubstituted –C_{2-6} alkyl, -CH_2OH, -$CH_2N(R^{13b})_2$, -C_{1-3} haloalkyl, F, I, -OR^{13a}, CF_3, and CN;

R^{12d} is 2-5 substituents, each independently selected at each occurrence from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{13b})_2$, -C_{1-3} haloalkyl, F, Br, I, -OR^{13}, CF_3, and CN;

each R^{13} is independently selected from the group consisting of unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{13a} is independently selected from the group consisting of unsubstituted –C_{2-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{13b} is independently selected from the group consisting of H and unsubstituted $-C_{1-3}$ alkyl; and

q is an integer of 1 to 5.

98. The compound of claim 97, wherein the compound of Formula **IIIc** is selected from the group consisting of:



or a pharmaceutically acceptable salt thereof.

99. A compound , of Formula **IIId**:



IIId

or a pharmaceutically acceptable salt thereof,

wherein:

R^{14} is selected from the group consisting of unsubstituted $-C_{1-6}$ alkyl, $-C_{1-3}$ haloalkyl, and CF_3;

R^{15} is selected from the group consisting of unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{16} is independently selected at each occurrence from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{17b})_2$, -C_{1-3} haloalkyl, halide, -OR^{17a}, CF_3, and CN;

each R^{17a} is independently selected from the group consisting of unsubstituted –C_{3-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{17b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl; and

q is an integer of 1 to 5.

100. The compound of claim 99, wherein the compound of Formula **IIId** is selected from the group consisting of:



or a pharmaceutically acceptable salt thereof.

101. A compound , of Formula **IV**:



IV

or a pharmaceutically acceptable salt thereof,

wherein:

Ring F is  ;

Ring G is selected from the group consisting of  ,  ,  ,  , and a 5-6 membered heteroarylR^{19d}, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^{18} is independently selected at each occurrence from the group consisting of H, -C$_{1-3}$ haloalkyl, halide, -OR^{20}, CF$_3$, and CN;

R^{19a} is selected from the group consisting of H, unsubstituted –C$_{2-6}$ alkyl, -CH$_2$OH, -CH$_2$N(R^{21})$_2$, -C$_{1-3}$ haloalkyl, F, Br, I, -OR^{20}, CF$_3$, and CN;

each R^{19b} is independently selected at each occurrence from the group consisting of H, unsubstituted –C$_{2-6}$ alkyl, -CH$_2$OH, -CH$_2$N(R^{21})$_2$, -C$_{1-3}$ haloalkyl, halide, -OR^{20}, CF$_3$, and CN;

R^{19c} is 2-5 substituents, each independently selected at each occurrence from the group consisting of H, -CH$_2$OH, -CH$_2$N(R^{21})$_2$, -C$_{1-3}$ haloalkyl, halide, -OR^{20}, CF$_3$, and CN;

R^{19d} is 1-4 substituents, each independently selected at each occurrence from the group consisting of H, -CH$_2$OH, -CH$_2$N(R^{21})$_2$, -C$_{1-3}$ haloalkyl, halide, -OR^{20}, CF$_3$, and CN;

each R^{20} is independently selected from the group consisting of H, unsubstituted –C$_{3-6}$ alkyl, -C$_{1-3}$ haloalkyl, and CF$_3$;

each R^{21} is independently selected from the group consisting of H and unsubstituted –C$_{1-3}$ alkyl;

p is an integer of 1 to 13; and

r is an integer of 1 to 5.

102. The compound of claim 101, wherein the compound of Formula IV is selected from the group consisting of:



 ,  ,  , and

 ,

or a pharmaceutically acceptable salt thereof.

103. A compound selected from the group consisting of:

 and  ,

or a pharmaceutically acceptable salt thereof.

104. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1-103, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

105. The pharmaceutical composition according to claim 104, wherein the composition is a component in a compound-eluting coating for a medical device.

106. A method of treating a disorder or disease selected from the group consisting of a neurodegenerative disease, eye disease, osteoporosis, osteoarthropathy, osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, oral mucositis, gastrointestinal mucositis, craniofacial defects, and oncolytic bone disease, the method comprising administering to the patient a therapeutically effective amount of a compound according to any one of claims 1-103, or a pharmaceutically acceptable salt thereof.

107. The method of claim 106, wherein the disorder or disease is a neurodegenerative disease.

108. The method according to any one of claims 106-107, wherein the neurodegenerative disease is Parkinson's disease, stroke, spinal cord injury, ischemic cerebral disease, epilepsy, Alzheimer's disease, dementia, depression, bipolar disorder, or schizophrenia.

109. The method of claim 106, wherein the disorder or disease is an eye disease.

110. The method according to any one of claims 106 and 109, wherein the eye disease is wet age-related macular degeneration, dry age-related macular degeneration, geographic atrophy, diabetic retinopathy, diabetic macular edema, retinal detachment, retinal degeneration, retinal vein occlusion, retinopathy of prematurity, retinitis pigmentosa, retinopathies, Leber congenital amaurosis and glaucoma.

111. The method of claim 106, wherein the disorder or disease is osteoporosis, osteoarthropathy, osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, oral mucositis, gastrointestinal mucositis, craniofacial defects, or oncolytic bone disease.

112. A method of treating a disorder or disorder or disease related to differentiation and growth of stem cells and is selected from the group consisting of hair loss, hematopoiesis related diseases, tissue regeneration related diseases, and other diseases associated with abnormalities in development, stem cell differentiation, and cell proliferation, the method comprising administering to the patient a therapeutically effective amount of a compound according to any one of claims 1-103, or a pharmaceutically acceptable salt thereof.

113. The method of claim 106 or 112, wherein the patient is a mammal.

114. The method of claim 113, wherein the mammal is a human.

115. The method of claim 106, wherein the compound activates one or more proteins in the Wnt pathway.

116. The method of claim 115, wherein the compound activates signaling induced by one or more Wnt proteins.

117. The method according to any one of claims 106 and 115-116, wherein the one or more Wnt proteins are selected from the group consisting of: WNT1, WNT2, WNT2B, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, and WNT16.

118. A compound-eluting coating or a controlled release system comprising a compound according to any one of claims 1-103, or a pharmaceutically acceptable salt thereof.

119. A medical device comprising a compound according to any one of claims 1-103, or a pharmaceutically acceptable salt thereof.

120. An implant, sponge, polymer, ointment, cream or gel composition suitable for *in vivo* use comprising a compound according to any one of claims 1-103, or a pharmaceutically acceptable salt thereof.

WHAT IS CLAIMED IS:

1. A compound of Formula **Ia**:



Ia

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is  ;

Ring B is selected from the group consisting of  ,  , and ;

each R^1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2a} is selected from the group consisting of unsubstituted –C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, Cl, Br, I, -OR^{3a}, CF_3, and CN;

R^{2b} is selected from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^{3a}, CF_3, and CN;

R^{2c} is 2-5 substituents, each independently selected at each occurrence from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2d} is 1-4 substituents, each independently selected at each occurrence from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2e} is 1-4 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2f} is 1-3 substituents, each independently selected at each occurrence from the group consisting of unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2g} is 1-3 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3a} is independently selected from the group consisting of unsubstituted –C_{2-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each W is N or C, wherein at least two W are N;

each U is N or C, wherein at least one U is N and at least one U is C;

G is NH or O;

each J is N or C, wherein at least one J is C; and

n is an integer of 1 to 7.

2. The compound of claim 1, wherein R^1 is selected from the group consisting of H, F, Cl, Me, OMe, OH, CF_3 and CN; and n is 1 or 2.

3. The compound of claim 1, wherein R^1 is H.

4. The compound of claim 1, wherein R^1 is F; and n is 1.

5. The compound of any one of claims 1-4, wherein Ring B is a substituted phenyl.

6. The compound of any one of claims 1-4, wherein 

is selected from the group consisting of 

, 

, 

, 

, 

, and 

.

7. The compound of claim 1, wherein the compound of Formula **Ia** is selected from the group consisting of:



, 

, 

,



, 

, 

,



, 

, 

,



, 

, 

,



, 

, 

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



or a pharmaceutically acceptable salt thereof.

8. A compound of Formula **Ib**:



Ib

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is  ;

Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^2 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted -C_{1-3} alkyl;

each M is independently selected from the group consisting of N, C, S and O, wherein both M are not O and both M are not C;

m is an integer of 1 to 5; and

n is an integer of 1 to 10.

9. The compound of claim 8, wherein the compound of Formula **Ib** is selected from the group consisting of:




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

, and

,

or a pharmaceutically acceptable salt thereof.

10. A compound of Formula **Ic**:



Ic

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is 

;

Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^2 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each M is independently selected from the group consisting of N, C, S and O, wherein if one M is C, the other M is selected from the group consisting of N, S, and O;

m is an integer of 1 to 5; and

n is an integer of 1 to 10.

11. The compound of claim 10, wherein the compound of Formula **Ic** is selected from the group consisting of:




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



or a pharmaceutically acceptable salt thereof.

12. A compound of Formula **Id**:



Id

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is  ;

Ring B is selected from the group consisting of  ,  , and a 5-6 membered heteroarylR^{2e}, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2a} is selected from the group consisting of H, unsubstituted –C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, Cl, Br, I, -OR^{3a}, CF_3, and CN;

R^{2b} is selected from the group consisting of H, unsubstituted –C_{2-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, F, I, -OR^3, CF_3, and CN;

R^{2c} is selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, F, Br, I, -OR^3, CF_3, and CN;

R^{2d} is 2-5 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2e} is 1-3 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted - C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3a} is independently selected from the group consisting of H, unsubstituted – C_{2-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

Q is S or NH; and

n is an integer of 1 to 5.

13. The compound of claim 12, wherein the compound of Formula **Id** is selected from the group consisting of:





or a pharmaceutically acceptable salt thereof.

14. A compound of Formula **Ie**:



Ie

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is  ;

Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^2 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each W is N or C, wherein at least one W is N;

Q is S or NH;

m is an integer of 1 to 5; and

n is an integer of 1 to 4.

15. The compound of claim 14, wherein the compound of Formula **Ie** is selected from the group consisting of:





or a pharmaceutically acceptable salt thereof.

16. A compound of Formula **If**:



If

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is  ;

Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^2 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each W is N or C;

m is an integer of 1 to 5; and

n is an integer of 1 to 5.

17. A compound of Formula **Ig**:



Ig

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is 

;

Ring B is selected from the group consisting of 

, 

, 

, 

, and a 5-6 membered heteroarylR^{2d}, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

R^{2a} is selected from the group consisting of unsubstituted –C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, F, I, -OR^3, CF_3, and CN;

R^{2b} is selected from the group consisting of unsubstituted $-C_{2-6}$ alkyl, $-CH_2OH$, $-CH_2N(R^{3b})_2$, $-C_{1-3}$ haloalkyl, halide, $-OR^3$, CF_3, and CN;

R^{2c} is 2-5 substituents, each independently selected at each occurrence from the group consisting of unsubstituted $-C_{1-6}$ alkyl, $-CH_2OH$, $-CH_2N(R^{3b})_2$, $-C_{1-3}$ haloalkyl, halide, $-OR^3$, CF_3, and CN;

R^{2d} is 1-3 substituents, each independently selected at each occurrence from the group consisting of H, unsubstituted $-C_{1-6}$ alkyl, $-CH_2OH$, $-CH_2N(R^{3b})_2$, $-C_{1-3}$ haloalkyl, halide, $-OR^3$, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted $-C_{1-6}$ alkyl, $-C_{1-3}$ haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted $-C_{1-3}$ alkyl;

Q is selected from the group consisting of O, S, and NH; and

n is an integer of 1 to 5.

18. A compound of Formula **Ih**:



Ih

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is 

;

Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein at a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted $-C_{1-6}$ alkyl, $-C_{1-3}$ haloalkyl, halide, $-OR^3$, CF_3, and CN;

each R^2 is independently selected at each occurrence from the group consisting of H, unsubstituted $-C_{1-6}$ alkyl, $-CH_2OH$, $-CH_2N(R^{3b})_2$, $-C_{1-3}$ haloalkyl, halide, $-OR^3$, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each W is N or C, wherein at least one W is N;

Q is selected from the group consisting of O, S, and NH;

m is an integer of 1 to 5; and

n is an integer of 1 to 4.

19. A compound of Formula **Ii**:



Ii

or a pharmaceutically acceptable salt thereof,

wherein:

Ring A is 

, wherein a carbon atom on the ring is attached to the carbonyl carbon;

Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon;

each R^1 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^2 is independently selected at each occurrence from the group consisting of H, unsubstituted -C_{1-6} alkyl, -CH_2OH, -$CH_2N(R^{3b})_2$, -C_{1-3} haloalkyl, halide, -OR^3, CF_3, and CN;

each R^3 is independently selected from the group consisting of H, unsubstituted -C_{1-6} alkyl, -C_{1-3} haloalkyl, and CF_3;

each R^{3b} is independently selected from the group consisting of H and unsubstituted –C_{1-3} alkyl;

each W is N or C, wherein at least one W is C;

Q is selected from the group consisting of O, S, and N;

m is an integer of 1 to 5; and

n is an integer of 1 to 7.

20. The compound of claim 19, wherein the compound of Formula **Ii** is selected from the group consisting of:




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,







and


or a pharmaceutically acceptable salt thereof.

21. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1-20, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

22. The pharmaceutical composition according to claim 21, wherein the composition is a component in a compound-eluting coating for a medical device.

23. Use of a therapeutically effective amount of a compound according to any of the claims 1-20, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disorder or disease in a patient, wherein the disorder or disease is selected from the group consisting of a neurodegenerative disease, eye disease, osteoporosis, osteoarthropathy, osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, oral mucositis, gastrointestinal mucositis, craniofacial defects, and oncolytic bone disease.

24. The use according to claim 23, wherein the disorder or disease is a neurodegenerative disease.

25. The use according to any one of claims 23-24, wherein the neurodegenerative disease is Parkinson's disease, stroke, spinal cord injury, ischemic cerebral disease, epilepsy, Alzheimer's disease, dementia, depression, bipolar disorder, or schizophrenia.

26. The use according to claim 23, wherein the disorder or disease is an eye disease.

27. The use according to claim 23 or 26, wherein the eye disease is wet age-related macular degeneration, dry age-related macular degeneration, geographic atrophy, diabetic retinopathy, diabetic macular edema, retinal detachment, retinal degeneration, retinal vein occlusion, retinopathy of prematurity, retinitis pigmentosa, retinopathies, Leber congenital amaurosis and glaucoma.

28. The use according to claim 23, wherein the disorder or disease is osteoporosis, osteoarthropathy, osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, oral mucositis, gastrointestinal mucositis, craniofacial defects, or oncolytic bone disease.

29. Use of a therapeutically effective amount of a compound according to any of the claims 1-20, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disorder or disease in a patient, wherein the disorder or disease is related to differentiation and growth of stem cells such as alopecia, hair loss, hematopoiesis related diseases, tissue regeneration related diseases and other diseases associated with abnormalities in development, stem cell differentiation and cell proliferation.

30. The use according to claim 23 or 29, wherein the patient is a mammal.

31. The use according to claim 30, wherein the mammal is a human.

32. A compound-eluting coating or a controlled release system comprising a compound according to any one of claims 1-20, or a pharmaceutically acceptable salt thereof.

33. A medical device comprising a compound according to any one of claims 1-20, or a pharmaceutically acceptable salt thereof.

34. An implant, sponge, polymer, ointment, cream or gel composition suitable for *in vivo* use comprising a compound according to any one of claims 1-20, or a pharmaceutically acceptable salt thereof.